JP2012511545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012511545A5 JP2012511545A5 JP2011540102A JP2011540102A JP2012511545A5 JP 2012511545 A5 JP2012511545 A5 JP 2012511545A5 JP 2011540102 A JP2011540102 A JP 2011540102A JP 2011540102 A JP2011540102 A JP 2011540102A JP 2012511545 A5 JP2012511545 A5 JP 2012511545A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- polypeptide according
- variable domain
- single variable
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 7
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 7
- 230000033115 angiogenesis Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 101100481404 Danio rerio tie1 gene Proteins 0.000 claims 3
- 101100216078 Mus musculus Ang4 gene Proteins 0.000 claims 3
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 claims 3
- 102100034594 Angiopoietin-1 Human genes 0.000 claims 2
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 claims 2
- 101000693093 Homo sapiens Angiopoietin-related protein 1 Proteins 0.000 claims 2
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 claims 2
- 101000924549 Homo sapiens Angiopoietin-related protein 6 Proteins 0.000 claims 2
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 102000052496 human ANGPTL1 Human genes 0.000 claims 2
- 102000055659 human ANGPTL4 Human genes 0.000 claims 2
- 102000055024 human ANGPTL6 Human genes 0.000 claims 2
- 102000052216 human VPS51 Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 101150054149 ANGPTL4 gene Proteins 0.000 claims 1
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 1
- -1 Angptl1 Proteins 0.000 claims 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 1
- 101000693081 Homo sapiens Angiopoietin-related protein 2 Proteins 0.000 claims 1
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 claims 1
- 101000924346 Homo sapiens Angiopoietin-related protein 5 Proteins 0.000 claims 1
- 101100323232 Mus musculus Ang3 gene Proteins 0.000 claims 1
- 101100001703 Mus musculus Angptl2 gene Proteins 0.000 claims 1
- 101100001705 Mus musculus Angptl3 gene Proteins 0.000 claims 1
- 101100434901 Mus musculus Angptl6 gene Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000057758 human ANGPTL2 Human genes 0.000 claims 1
- 102000053580 human ANGPTL3 Human genes 0.000 claims 1
- 102000051085 human ANGPTL5 Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12122808P | 2008-12-10 | 2008-12-10 | |
| US61/121,228 | 2008-12-10 | ||
| PCT/EP2009/066822 WO2010066836A2 (en) | 2008-12-10 | 2009-12-10 | Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012511545A JP2012511545A (ja) | 2012-05-24 |
| JP2012511545A5 true JP2012511545A5 (enExample) | 2013-01-24 |
| JP5823871B2 JP5823871B2 (ja) | 2015-11-25 |
Family
ID=42026361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011540102A Expired - Fee Related JP5823871B2 (ja) | 2008-12-10 | 2009-12-10 | 血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン／Ｔｉｅシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8858940B2 (enExample) |
| EP (1) | EP2364328A2 (enExample) |
| JP (1) | JP5823871B2 (enExample) |
| CN (1) | CN102307902B (enExample) |
| AU (2) | AU2009324354B2 (enExample) |
| CA (1) | CA2746395C (enExample) |
| WO (1) | WO2010066836A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| EA201500156A3 (ru) | 2008-01-03 | 2017-09-29 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8858940B2 (en) | 2008-12-10 | 2014-10-14 | Ablynx N.V. | Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| CA2865464C (en) * | 2012-03-30 | 2022-07-12 | Boehringer Ingelheim International Gmbh | Ang2-binding molecules |
| WO2014144600A2 (en) | 2013-03-15 | 2014-09-18 | Viktor Roschke | Multivalent and monovalent multispecific complexes and their uses |
| KR102131371B1 (ko) | 2013-07-02 | 2020-07-08 | 삼성전자주식회사 | Ang-2 특이적 항체 및 그의 용도 |
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| TW201613977A (en) | 2014-08-07 | 2016-04-16 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
| US9771417B2 (en) | 2014-08-07 | 2017-09-26 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
| MA41899A (fr) | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
| WO2017020001A2 (en) * | 2015-07-29 | 2017-02-02 | Allergan, Inc. | Heavy chain only antibodies to ang-2 |
| WO2018087727A1 (en) * | 2016-11-14 | 2018-05-17 | Novartis Ag | Methods and compositions for treatment of cartilage damage and arthritis |
| JP7107968B2 (ja) * | 2017-01-13 | 2022-07-27 | ヴァゾミューン セラピューティクス インコーポレイテッド | 血管新生を促進する薬剤ならびにその方法および使用 |
| KR101955886B1 (ko) * | 2017-05-05 | 2019-03-12 | 주식회사 유비프로틴 | 안지오포이에틴-1 반감기를 증가시키는 방법 |
| WO2021102173A1 (en) * | 2019-11-21 | 2021-05-27 | Unity Biotechnology | Antibodies directed to tie-2 and methods of use |
| CN118251412A (zh) * | 2021-09-10 | 2024-06-25 | 海南康哲维盛科技有限公司 | 抗ang2抗体及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US6365154B1 (en) | 1998-09-28 | 2002-04-02 | Smithkline Beecham Corporation | Tie2 agonist antibodies |
| US6376653B1 (en) * | 1998-09-28 | 2002-04-23 | Smithkline Beecham Plc | Tie2 antagonist antibodies |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| WO2005018629A1 (en) | 2003-08-12 | 2005-03-03 | Yarbrough William M | Treatment for acne vulgaris and method of use |
| US7348001B2 (en) * | 2003-08-12 | 2008-03-25 | Dyax Corp. | Tie1-binding ligands |
| ES2364147T3 (es) * | 2004-01-16 | 2011-08-25 | Regeneron Pharmaceuticals, Inc. | Polipéptidos de fusión capaces de activar receptores. |
| WO2006005361A1 (en) | 2004-07-13 | 2006-01-19 | Centre National De La Recherche Scientifique | Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| TW200804593A (en) | 2006-01-24 | 2008-01-16 | Domantis Ltd | Fusion proteins that contain natural junctions |
| AU2007227251A1 (en) | 2006-03-20 | 2007-09-27 | Amgen Fremont, Inc. | Antibodies directed to angiopoietin-like protein 4 and uses thereof |
| EP2057191A1 (en) * | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| WO2008089070A2 (en) * | 2007-01-12 | 2008-07-24 | Dyax Corp. | Combination therapy for the treatment of cancer |
| EP2205277B1 (en) * | 2007-10-22 | 2017-07-26 | Genmab A/S | Novel antibody therapies |
| CA2706425A1 (en) * | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| DK2285408T3 (en) * | 2008-06-05 | 2019-02-04 | Ablynx Nv | AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES |
| US8858940B2 (en) | 2008-12-10 | 2014-10-14 | Ablynx N.V. | Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
-
2009
- 2009-12-10 US US13/133,685 patent/US8858940B2/en active Active
- 2009-12-10 EP EP09768527A patent/EP2364328A2/en not_active Withdrawn
- 2009-12-10 JP JP2011540102A patent/JP5823871B2/ja not_active Expired - Fee Related
- 2009-12-10 WO PCT/EP2009/066822 patent/WO2010066836A2/en not_active Ceased
- 2009-12-10 AU AU2009324354A patent/AU2009324354B2/en not_active Ceased
- 2009-12-10 CA CA2746395A patent/CA2746395C/en not_active Expired - Fee Related
- 2009-12-10 CN CN200980158260.9A patent/CN102307902B/zh not_active Expired - Fee Related
-
2014
- 2014-09-04 US US14/476,802 patent/US9382333B2/en active Active
-
2016
- 2016-05-18 US US15/157,972 patent/US9822175B2/en active Active
- 2016-05-25 AU AU2016204023A patent/AU2016204023B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012511545A5 (enExample) | ||
| Shyu et al. | Homing genes, cell therapy and stroke | |
| JP2016509011A5 (enExample) | ||
| EP4378487A3 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| JP2016521688A5 (enExample) | ||
| EP4272728A3 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
| WO2020057541A8 (en) | Anti-ifnar1 antibodies for treating autoimmune diseases | |
| JP2017532343A5 (enExample) | ||
| JP2013107899A5 (enExample) | ||
| WO2009044273A3 (en) | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response | |
| JP2017537612A5 (enExample) | ||
| WO2010081082A3 (en) | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | |
| EP3308798A3 (en) | Polypeptides and antibodies for treating hbv infection and related diseases | |
| JP2016502515A5 (enExample) | ||
| JP2011528895A5 (enExample) | ||
| JP2017523985A5 (enExample) | ||
| MX2020006822A (es) | Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa. | |
| JP2014513941A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2014525394A5 (enExample) | ||
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| NZ599930A (en) | Pharmaceutical compositions for the stimulation of stem cells. | |
| JP2019531293A5 (enExample) | ||
| RU2016108808A (ru) | Терапевтическое применение vegf-c и ccbe1 | |
| ZA202201828B (en) | Therapeutic fusion proteins |